Abstract
The present study is an attempt to formulate and evaluate Teneligliptin hydrobromide hydrate pellets. Teneligliptin is a potent, selective DPP-4 inhibitor, which is believed to exert its actions in diabetes mellitus patients. Teneligliptin increases insulin release and decreases glucagon levels in the circulation in a glucose dependent manner. The Teneligliptin pellets were prepared by using blend of MCC, Lactose, Crospovidone and PVP K-30. Pellet formulation was optimized for formulation parameters (concentration of Crosspovidone and PVP K-30) using 32 factorial design. FTIR studies showed absence of chemical interaction between the drug and polymer. The pellets were prepared and evaluated in terms of bulk density, tapped density, angle of repose and in-vitro release study. In-vitro release of drug was compared with in-vitro release of drug from marketed formulation (Dynaglipt Tablet).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
